Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clinical Trial Enrollment

- PMLiVE

Takeda and Degron enter molecular glue degrader partnership worth over $1.2bn

The companies will focus on targets in oncology, neuroscience and inflammation

- PMLiVE

Agenda announced for FlyPharma Vienna 2024

The conference will take place on 23 to 24 October at Vienna AirportCity

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

- PMLiVE

Bristol Myers Squibb unveils ten-year strategy to improve access to medicines in LMICs

The company has collaborated with the ATOM Coalition to make Opdivo available in select countries

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

- PMLiVE

Consolidation in healthcare marketing

By Tony Walford

Medscape Education and KDIGO Nephrology Collaboration Accelerates Improvements to Patient Care

Ahead of the 61st European Renal Association (ERA) Congress, Medscape Education and KDIGO (Kidney Disease: Improving Global Outcomes) announce an educational collaboration through a series of webinars to improve anemia-related...

Medscape Education Global

Biogen Idec building

Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition

The company will gain access to HI-Bio’s lead asset for immune-mediated and rare diseases

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn’s disease

The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

- PMLiVE

LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

The rare neurodegenerative disease affects one in every 300 people in the UK

- PMLiVE

Nurturing the power of true connections in your clinical trials

By Scott Palmer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links